# CelerisTx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celeristx

- Industry: Biotechnology
- Headquarters: Graz, Austria
- Website: www.celeristx.com
- Total disclosed funding: $4.4M
- Latest round: Seed (Feb 10, 2022)
- Investors on record: 5

## About

Founded in 2021 by its CEO, DI Christopher Trummer, and CFO/COO, Jakob Hohenberger, and based in Graz, Austria, Celeris Therapeutics GmbH, doing business as CelerisTx, operates as a pharmaceutical solution that treats diseases with high unmet medical needs. In February 2022, CelerisTx raised 4.4 million in seed funding from investors Apex Ventures, i&i Biotech Fund, and Pace Ventures Enigma, with participation from returning investors Longevity Tech Fund and R42.

The company offers a digital platform, Celeris® One™, used for the design of proximity-inducing compounds (PICs™). The company offers machine learning-driven retrosynthesis and a robotized synthesis lab that offers autophagy, folding via chaperones, lysosomal and ubiquitin-mediated proteolysis play, including 3-dimensional structural data.

The company plans to use the February 2022 funding to accelerate its pipeline of novel proximity-inducing compounds.

## Funding rounds

- Seed, Feb 10, 2022, $4.4M — Apex Ventures, Longevity Tech Fund, R42, i&i Bio, Pace Ventures Enigma

## Investors

- Apex Ventures (https://capitalatlas.ai/funds/apex-ventures) — Seed
- Longevity Tech Fund (https://capitalatlas.ai/funds/longevity-tech-fund) — Seed
- R42 (https://capitalatlas.ai/funds/r42) — Seed
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Seed
- Pace Ventures Enigma (https://capitalatlas.ai/funds/pace-ventures-enigma) — Seed